Method: Consecutive breast tumour cases were selected by systematic retrospective archive search and were examined by breast cancer panel. If expression of oestrogen and progesterone receptors and HER2 protein was negative, mammaglobin, cytokeratin AE1/AE3, vimentin, CD45, CDX2, cytokeratin 20, TTF-1 and melanosome protein HMB-45 were detected. Results: Five patients (0.89 %, 95 % CI=0.38-2.10 %) with secondary breast tumours were identified among 559 cases. Breast was affected by metastatic small cell lung cancer (1), malignant neuroendocrine tumour of small intestine (1) as well as by epithelioid melanoma metastasis in breast tissues (2) or intramammary lymph node (1). Analysing medical records, multiple synchronous and/or metachronous metastasis, involving brain, kidneys and ovaries, were found in all patients with haematogenous tumour metastases in the breast. In contrast, the lymphogenic tumour spread was isolated. Conclusion: 1. Lymphogenic or haematogenous metastasis rarely (0.89 % of malignant breast tumours by morphology) can develop in breast tissues. It should be taking into account when planning the differential diagnostic approach, especially immunohistochemistry. 2. Haematogenous metastases in breast are associated with a wide synchronous or metachronous extramammary tumour spread.